| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 10871823 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 163 journal articles in the PubMed database | Email to a friend | | |
| Ciccarelli O, Bagnato F, Mainero C, et al.
Antinuclear antibodies and response to IFNbeta-1a therapy in relapsing-remitting multiple sclerosis. [Journal Article]
Mult Scler 2000 Jun; 6(3):137-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Kappos L, Traboulsee A, Constantinescu C, et al.
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
Neurology 2006 Sep 26; 67(6):944-53.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Pozzilli C, Prosperini L, Sbardella E, et al.
Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. [Clinical Trial, Journal Article]
Neurol Sci 2005 Dec.:S174-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Río J, Tintoré M, Nos C, et al.
Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. [Clinical Trial, Journal Article]
J Neurol 2005 Jul; 252(7):795-800.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Gasperini C, Paolillo A, Giugni E, et al.
MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a. [Journal Article]
Mult Scler 2002 Apr; 8(2):119-23.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Khan OA, Tselis AC, Kamholz JA, et al.
A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. [Clinical Trial, Journal Article]
Eur J Neurol 2001 Mar; 8(2):141-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Petersen B, Bendtzen K, Koch-Henriksen N, et al.
Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis. [Journal Article]
Mult Scler 2006 Jun; 12(3):247-52.
Abstract | Full Citation | Find Related Articles | | Khademi M, Wallström E, Andersson M, et al.
Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis. [Clinical Trial, Controlled Clinical Trial, Journal Article]
J Neuroimmunol 2000 Mar 1; 103(2):202-10.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Koch-Henriksen N, Sørensen PS
The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group. [Clinical Trial, Journal Article, Randomized Controlled Trial]
Mult Scler 2000 Jun; 6(3):172-5.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
